Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Non Operating Income (2016 - 2023)

Historic Non Operating Income for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $47.5 million.

  • RedHill Biopharma's Non Operating Income rose 55885.02% to $47.5 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$8.9 million, marking a year-over-year increase of 7204.9%. This contributed to the annual value of $6.3 million for FY2024, which is 4376.99% down from last year.
  • As of Q2 2023, RedHill Biopharma's Non Operating Income stood at $47.5 million, which was up 55885.02% from -$21.2 million recorded in Q1 2023.
  • RedHill Biopharma's Non Operating Income's 5-year high stood at $47.5 million during Q2 2023, with a 5-year trough of -$63.9 million in Q4 2022.
  • Over the past 5 years, RedHill Biopharma's median Non Operating Income value was $2.1 million (recorded in 2019), while the average stood at -$1.5 million.
  • As far as peak fluctuations go, RedHill Biopharma's Non Operating Income skyrocketed by 4652222.22% in 2020, and later crashed by 73906.55% in 2021.
  • RedHill Biopharma's Non Operating Income (Quarter) stood at -$73000.0 in 2019, then surged by 6432.88% to $4.6 million in 2020, then crashed by 739.07% to -$29.5 million in 2021, then plummeted by 116.18% to -$63.9 million in 2022, then surged by 174.36% to $47.5 million in 2023.
  • Its last three reported values are $47.5 million in Q2 2023, -$21.2 million for Q1 2023, and -$63.9 million during Q4 2022.